Investigational drug · Phase 3
tirapazamine
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HCC, Hepatocellular Carcinoma, Gastrointestinal Cancer Metastatic.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
22
Any phase or sponsor naming "tirapazamine"
First trial start
2014
Sep 2014
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "tirapazamine", any sponsor or status.
- Phase 212
Conditions studied
As listed on its trial records.
- HCC
- Hepatocellular Carcinoma
- Gastrointestinal Cancer Metastatic
- Neuroendocrine Tumors
Approved drugs for the same conditions: Liver cancer (hepatocellular carcinoma) · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "tirapazamine" as an intervention, largest first.
- Concomitant Radiation and Cisplatin With and Without Tirapazamine in Treatment of Advanced Head and Neck CancerPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00094081 · 861 participants · Start Oct 2002 · Primary completion Sep 2006
Drug: tirapazamine (SR259075); cisplatin · For: Head and Neck Neoplasms
Sites: Phoenix, Arizona; Palo Alto, California; Tampa, Florida · 10 sites in all
- Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical CancerPivotal-lookingTerminated
National Cancer Institute (NCI)NIH
NCT00262821 · 402 participants · Start Feb 2006 · Primary completion Aug 2010
Drug: cisplatin; tirapazamine · For: Cervical Adenocarcinoma; Cervical Adenosquamous Cell Carcinoma; Cervical Squamous Cell Carcinoma and 5 more
Sites: Birmingham, Alabama; Mobile, Alabama; Anchorage, Alaska · 282 sites in all
- TRACE: Tirapazamine-Radiation And Cisplatin EvaluationPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT00174837 · 317 participants · Start Apr 2005 · Primary completion Jan 2008
Drug: Tirapazamine; Cisplatin · For: Head and Neck Squamous Cell Carcinoma
Sites: Bridgewater, New Jersey; Buenos Aires, Argentina; Cove, Australia · 17 sites in all
- A Phase II/III Trial Comparing Transarterial Tirapazamine Embolization (TATE) With cTACE for Intermediate-stage Liver Cancer.Pivotal-lookingRecruiting
Zhejiang Raygene Pharmaceuticals Co., LtdIndustry
NCT06844357 · 300 participants (planned) · Start Mar 27, 2025 · Primary completion Apr 1, 2029
Drug: tirapazamine · For: HCC
Sites: Nanjing, China; Lishui, China
- Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive RhabdomyosarcomaPivotal-lookingCompleted
National Cancer Institute (NCI)NIH
NCT00025363 · 150 participants · Start Nov 2001 · Primary completion Oct 2007
Drug: vincristine sulfate; irinotecan hydrochloride and 7 more · For: Alveolar Childhood Rhabdomyosarcoma; Embryonal Childhood Rhabdomyosarcoma; Embryonal-botryoid Childhood Rhabdomyosarcoma and 2 more
Sites: Arcadia, California
- TATE and Pembrolizumab (MK3475) in mCRC and NSCLCPivotal-lookingRecruiting
Teclison Ltd.Industry
NCT04701476 · 110 participants (planned) · Start May 20, 2021 · Primary completion Mar 31, 2027
Drug: TATE and pembrolizumab; TAS-102 pill and 1 more · For: Colorectal Cancer; Lung Cancer
Sites: Orange, California; Hsinchu, Taiwan; Taichung, Taiwan
National Cancer Institute (NCI)NIH
NCT00066742 · 72 participants · Start Sep 2003 · Primary completion Aug 2009
Drug: tirapazamine; cisplatin and 1 more · For: Limited Stage Small Cell Lung Cancer
Sites: San Antonio, Texas
Stanford UniversityAcademic, hospital or other
NCT00002774 · 63 participants · Start Jun 1996 · Primary completion Jun 2000
Drug: Tirapazamine; Cisplatin and 1 more · For: Squamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)
Sites: Palo Alto, California; Stanford, California
SWOG Cancer Research NetworkResearch network
NCT00003369 · 56 participants · Start Aug 1998 · Primary completion Oct 2003
Drug: cisplatin; tirapazamine · For: Cervical Cancer
Sites: Mobile, Alabama; Phoenix, Arizona; Tucson, Arizona · 85 sites in all
Teclison Ltd.Industry
NCT03259867 · 54 participants (planned) · Start Jul 1, 2017 · Primary completion Dec 30, 2026
Drug: Nivolumab Injectable Product · For: Hepatocellular Carcinoma; Gastric Cancer
Sites: Orange, California; Oklahoma City, Oklahoma; Milwaukee, Wisconsin
Newest research
PubMed records naming it or its code names, newest first.
- Dual-scaffold imageable embolic system with microenvironment normalization enhances hypoxia-activated chemoembolization for HCC.
Qi Z, Huang S, Xiao F, et al. · Drug Deliv 2026
- B-cell maturation antigen -targeted Tirapazamine-loaded liposomes overcome hypoxia-induced drug resistance and metastasis in multiple myeloma.
Maksimos M, Muz B, Azab F, et al. · J Control Release 2026
- Bioorthogonal Click-to-Disassemble Phthalocyanine Nanoassemblies for Precise Chemo-Photodynamic Therapy against Hypoxic Tumors.
Shen J, Xue EY, Yang C, et al. · Adv Sci (Weinh) 2026
- Image-guided photothermal therapy in ovarian cancer using a pH-sensitive ICG/TPZ nanoliposome to overcome thermoresistance.
Liu Q, Wang J, Li J, et al. · Colloids Surf B Biointerfaces 2026
- A Microneedle Delivered Nanoplatform Triggering a Therapeutic Cascade in Osteosarcoma by Amplified Photo-Activated Immunochemotherapy.
Cao S, Tang Z, Han C, et al. · Int J Nanomedicine 2026
- An oxygen gradient chamber with simple geometry for generating oxygen gradients in hydrogel-based cell cultures within a well-plate-compatible format.
Fleischhammer TM, Bösing N, Bahnemann J, et al. · Front Bioeng Biotechnol 2026
Also in development for HCC
- ApatinibRIVO, RivoceranibPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- VRT106Phase 33 trials
Guangzhou Virotech Pharmaceutical Co., Ltd. · Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma, HCC
- INO-9012Phase 24 trials
Geneos Therapeutics · HCC, Glioblastoma, Urothelial Carcinoma
- GNOS-PV02Phase 22 trials
Geneos Therapeutics · HCC
- FOG-001Phase 21 trial
Parabilis Medicines, Inc. · Cancer, Colorectal Cancer, Solid Tumor
- PM1009Phase 21 trial
Biotheus Inc. · HCC, Liver Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.